Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DRI +10.1%, NBTX +6.5%, FDS +2.5%, STRL +1.5% (guidance)
Other news:
- EWTX +21.7% (announces top-line data of EDG-7500)
- ALGS +14.1% (to announce topline results from Phase 2a HERALD Study)
- MBLY +8.2% (Intel reaffirms majority stake in Mobileye, emphasizes focus on growth and autonomous driving leadership)
- ACET +6.8% (announces ADI-001 clinical biomarker data from the Phase 1 GLEAN trial)
- TRIB +6.7% (to initiate CGM market study in India in furtherance of intended collaboration with Bayer)
- PLUG +5.7% (contracts with BP and Iberdrola JV to supply PEM electrolyzers in Spain; Launches an Equipment Lease Financing Platform - Plug is Targeting >$150 million from a Combination of Debt Leverage & Customer Financing Solutions)
- TUSK +5.2% (wholly owned subsidiary, Cobra Acquisitions LLC, announces that previously disclosed Settlement Agreement with the Puerto Rico Electric Power Authority was approved by the Title III Court)
- PHI +5% (provides litigation update-Court granted final approval to PLDT's case-ending settlement on Sept 17)
- BLDR +4.1% (updates succession plan)
- AMKR +3.2% (exec chairman to retire)
- VST +2.7% (to acquire equity interests of Vistra Vision from minority investors, to become sole owner)
- PLTR +2.3% (awarded $99.8 mln U.S. Army contract)
- INTC +2.1% (Intel reaffirms majority stake in Mobileye, emphasizes focus on growth and autonomous driving leadership)
- GOOG +2% (YouTube details AI updates; to start integrating Google DeepMind's most capable model for generating video, Veo, into YouTube Shorts later this year)
- JCI +1.8% (launches update to Metasys)
- SNDX +1.4% (INCY and SNDX announce NEJM publication of data from Pivotal AGAVE-201 trial)
- TGT +1.4% (appoints Jim Lee as CFO)
- QGEN +1.3% (expands QIAcuity digital PCR offering)
- VSTO +1.2% (Board of Directors Is Committed to Exploring All Opportunities to Maximize the Value of Revelyst, Including a Potential Sale)
- RGEN +1% (to restate results due to timing recognition of product revenue; increases FY24 revenue guidance)
- INCY +1% (INCY and SNDX announce NEJM publication of data from Pivotal AGAVE-201 trial)